T-knife Therapeutics Revenue

Biotechnology Research • San Francisco, California, United States • 51-100 Employees

T-knife Therapeutics revenue & valuation

Annual revenue	$2,500,000
Revenue per employee	$36,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$8,000,000
Total funding	$110,000,000

Key Contacts at T-knife Therapeutics

Vida Farsam

Cmc Director

Elisa Kieback

Cto And Co-Founder

Mikhail Steklov

Associate Director T Cell Fitness

Rizwan Daudi

Associate Director Clinical Operations

Christian Leschke

Director Viral Vector Manufacturing

Company overview

Headquarters	San Francisco, California, United States
Phone number	+1493094892432
Website	t-knife.com
NAICS	541714
Keywords	Cell Therapy, Gene Therapy, Target Selection, Immunoncology, T Cell Receptor, Tcr Characterization, Tcr Gene Transfer, Tcr Generation, Adoptive T Cell Therapy, Cancer Testis Antigens, Neoantigens, Neoepitopes, Retroviral Vectors, Tumor Antigens, Tumor Immunology
Founded	2018
Employees	51-100
Socials

T-knife Therapeutics Email Formats

T-knife Therapeutics uses 2 email formats. The most common is {first initial}.{last name} (e.g., j.doe@t-knife.com), used 53.7% of the time.

Format	Example	Percentage
{first initial}.{last name}	j.doe@t-knife.com	53.7%
{first name}.{last name}	john.doe@t-knife.com	46.3%

About T-knife Therapeutics

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor (TCR) engineered T cell therapies (TCR-Ts), a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity. T-knife is advancing a portfolio of TCR-T product candidates against targets with high unmet medical need, including cancer testis antigens, oncoviral antigens and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.

Employees by Management Level

Total employees: 51-100

Seniority

Employees

Entry

Manager

Director

Employees by Department

T-knife Therapeutics has 28 employees across 8 departments.

Departments

Number of employees

Funding Data

Explore T-knife Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2021-09-02	5	$110,000,000

Funding Insights

$110,000,000

Total funding amount

$110,000,000

Most recent funding amount

Number of funding rounds

T-knife Therapeutics Tech Stack

Discover the technologies and tools that power T-knife Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Apache HTTP Server

Web servers

jQuery

JavaScript libraries

Google Tag Manager

Tag managers

BambooHR

Recruitment & staffing

HSTS

Security

Open Graph

Miscellaneous

Google Analytics

Analytics

OneTrust

Cookie compliance

DocuSign

Miscellaneous

Strato

Hosting

Microsoft 365

Frequently asked questions

T-knife Therapeutics is located in San Francisco, California, US.

You can reach T-knife Therapeutics at +1493094892432.

T-knife Therapeutics generates an estimated annual revenue of $2,500,000. This revenue figure reflects the company's market position and business performance in its industry.

T-knife Therapeutics has an estimated valuation of $8,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

T-knife Therapeutics was founded in 2018, making it 8 years old. The company has established itself as a significant player in its industry over this time.

T-knife Therapeutics has approximately 51-100 employees. The company continues to grow its workforce to support its business operations and expansion.

T-knife Therapeutics has raised a total of $110,000,000 across 1 funding rounds. This investment has helped the company grow and expand its operations.